COMMON STOCK PURCHASE WARRANT ROCK CREEK PHARMACEUTICALS, INC.Common Stock Purchase Warrant • October 15th, 2015 • Rock Creek Pharmaceuticals, Inc. • Medicinal chemicals & botanical products
Contract Type FiledOctober 15th, 2015 Company IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Maxim Partners LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the six (6) month anniversary of the Issuance Date set forth above (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Issuance Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Rock Creek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to 446,429 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 15th, 2015 • Rock Creek Pharmaceuticals, Inc. • Medicinal chemicals & botanical products • New York
Contract Type FiledOctober 15th, 2015 Company Industry JurisdictionThis REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October __, 2015, is by and among Rock Creek Pharmaceuticals, Inc., a Delaware corporation with offices located at 2040 Whitfield Ave., Ste. 300, Sarasota Florida 34240 (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 15th, 2015 • Rock Creek Pharmaceuticals, Inc. • Medicinal chemicals & botanical products • New York
Contract Type FiledOctober 15th, 2015 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 14, 2015, is by and among Rock Creek Pharmaceuticals, Inc., a Delaware corporation with offices located at 2040 Whitfield Ave., Ste. 300, Sarasota Florida 34240 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).